Advil — Competitive Intelligence Brief

Advil (ibuprofen) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal Anti-inflammatory Drug [EPC]. Area: Immunology.

marketed Nonsteroidal Anti-inflammatory Drug [EPC] Sodium-coupled monocarboxylate transporter 1, Acid-sensing ion channel 1, Aldo-keto reductase family 1 member C2 Immunology Small molecule

Target snapshot

Advil (ibuprofen) — Generic (originally Boots Group). Ibuprofen inhibits prostaglandin synthetase, reducing pain, fever, and inflammation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Advil TARGET	ibuprofen	Generic (originally Boots Group)	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	Sodium-coupled monocarboxylate transporter 1, Acid-sensing ion channel 1, Aldo-keto reductase family 1 member C2	1969-01-15
Xibrom	BROMFENAC	Bausch Health	marketed	Nonsteroidal Anti-inflammatory Drug	Prostaglandin G/H synthase 2	2005-01-01
DIPHENHYDRAMINE CITRATE	DIPHENHYDRAMINE CITRATE		marketed	Nonsteroidal Anti-inflammatory Drug [EPC]		2005-01-01
Nevanac	NEPAFENAC	Harrow Health	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	Prostaglandin G/H synthase 2	2005-01-01
Excedrin Extra Strength Pain Reliever	NSAID	Haleon Us Holdings	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	Cyclooxygenase	2004-01-01
Mobic	MELOXICAM	Boehringer Ingelheim	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	Prostaglandin G/H synthase 2	2000-01-01
Celebrex	celecoxib	Pfizer Inc. (originally Searle/Pharmacia)	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	COX-2	1998-12-31

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2029-09-30 — Advil · 9114068 · Method of Use · US
• 2029-09-30 — Advil · 8735452 · Method of Use · US
• 2029-09-30 — Advil · 9649284 · Method of Use · US
• 2029-09-30 — Advil · 9138404 · Method of Use · US
• 2029-09-30 — Advil · 8871810 · Method of Use · US
• 2029-09-30 — Advil · 9295639 · Method of Use · US
• 2030-05-26 — Mobic · 10709713 · Method of Use · US
• 2030-05-26 — Mobic · 11253478 · Formulation · US
• 2030-05-26 — Mobic · 9974746 · Formulation · US
• 2030-08-31 — Mobic · 8545879 · Formulation · US
• 2030-09-14 — Advil · 9012508 · Method of Use · US
• 2032-03-16 — Advil · 9072710 · Method of Use · US
• 2032-03-16 — Advil · 11806400 · Method of Use · US
• 2032-03-16 — Advil · 9072661 · Method of Use · US
• 2033-03-31 — Mobic · 9526734 · Formulation · US
• 2035-03-31 — Mobic · 9649318 · Formulation · US
• 2035-03-31 — Mobic · 9808468 · Method of Use · US
• 2036-05-27 — Celebrex · 10722456 · Formulation · US
• 2036-05-27 — Celebrex · 10799517 · Formulation · US
• 2036-05-27 — Celebrex · 9949990 · Formulation · US
• 2036-05-27 — Celebrex · 9795620 · Formulation · US
• 2036-05-27 — Celebrex · 9572819 · Formulation · US
• 2036-05-27 — Celebrex · 10376527 · Formulation · US
• 2039-03-08 — Mobic · 10881663 · Method of Use · US
• 2039-03-08 — Mobic · 11458145 · Method of Use · US
• 2040-07-19 — Mobic · 12059423 · Compound · US
• 2041-07-31 — Mobic · 12263176 · Formulation · US

Sponsor landscape (Nonsteroidal Anti-inflammatory Drug [EPC] class)

1. · 8 drugs in this class
2. Pfizer · 2 drugs in this class
3. Assiut University · 1 drug in this class
4. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class
5. Centro Hospitalar Lisboa Ocidental · 1 drug in this class
6. Dartmouth-Hitchcock Medical Center · 1 drug in this class
7. Dr. Vishwanath Karad MIT World Peace University · 1 drug in this class
8. Dr. Reddy's Laboratories Limited · 1 drug in this class
9. Generic (originally Boots Group) · 1 drug in this class
10. Boehringer Ingelheim · 1 drug in this class